Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis

NCT01164579 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01164579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01164579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
November 30, 2013
Enrollment
109 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis